

## LAMZEDE® INFUSION ORDER

(velmanase alfa-tycv)

### 1 PATIENT INFORMATION

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_  
 Primary Phone: \_\_\_\_\_ Gender: Male Female  
 Address: \_\_\_\_\_  
 City, State, Zip: \_\_\_\_\_  
 Allergy: \_\_\_\_\_  
 Patient Weight: \_\_\_\_\_ Lbs \_\_\_\_\_ Kg Date Weighed: \_\_\_\_\_  
 Venous Access Peripheral IV Port \_\_\_\_\_G \_\_\_\_\_ Inch needle  
 Device: PIV for port access complications

### 2 PRESCRIBER INFORMATION

Prescriber's Name: \_\_\_\_\_  
 Contact Person: \_\_\_\_\_ Phone: \_\_\_\_\_  
 NPI #: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City, State, Zip: \_\_\_\_\_  
 Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
 ICD-10 Diagnosis: *E77.1 (Defects in glycoprotein degradation) - Alpha-mannosidosis*

### 3 CATHETER ACCESS AND FLUSH PROTOCOL

ACCESS TYPE	CATHETER FLUSH ORDERS	
Peripheral PORT (Also include Peripheral IV for Port Malfunction)	<input checked="" type="checkbox"/> <b>0.9% Saline Flush:</b> Dispense: 30 Days Refills: x 1yr OR _____ Refills Flush line/port with 10mL for patency/SASH protocol. <b>Heparin Flush:</b> Dispense: 30 Days Refills: x 1yr OR _____ Refills Flush port with _____ mL of Heparin _____ units/mL per SASH protocol.	<b>CathFlo:</b> 2 mg/2 mL as directed. <i>Pharmacy authorized to dispense upon home health nurse validated port occlusion.</i> <input type="checkbox"/> Dispense: 1 Kit Refills: x 1yr OR _____ Refills

### 4 PRE-MEDICATION Premedication for administration 30-60 min. prior to drug infusion:

- Antiemetic: \_\_\_\_\_ q.s. 1 month Refill: x 1yr OR \_\_\_\_\_ Refills  Not Needed  
 Antihistamine: \_\_\_\_\_ q.s. 1 month Refill: x 1yr OR \_\_\_\_\_ Refills  Not Needed  
 Corticosteroid: \_\_\_\_\_ q.s. 1 month Refill: x 1yr OR \_\_\_\_\_ Refills  Not Needed  
 LMX 4 or (EMLA) Lidocaine 2.5%/Prilocaine 2.5% cream - Apply topically 1 hour prior to starting IV or accessing port QTY: 1 Refill: x 1yr OR \_\_\_\_\_ Refills  
 \_\_\_\_\_

### 5 TREATMENT REGIMEN

LAMZEDE DOSE	PRESCRIPTION
<input checked="" type="checkbox"/> 1mg/kg	Lamzede _____ mg IV every week _____ vials/infusion Disp: 28 days Refills: 12 months <i>Round up to the next whole vial (each 10mg vial to be reconstituted with 5mL Sterile Water to yield a concentration of 10mg/5mL)</i>

#### PREPARATION AND ADMINISTRATION

Total Infusion Volume is determined by patient's actual body weight and total number of reconstituted vials  
 Infusion Rate:  Infuse over 60 min (Patient weight < 50kg)  Infuse at 25mL/hr (Patient weight ≥ 50kg)  Other rate: \_\_\_\_\_  
 Infuse reconstituted Lamzede solution through in-line low protein-binding 0.2µ filter

#### SKILLED NURSING VISIT

- As needed for IV access, administration, and proper clinical monitoring Administration procedures to be followed per pharmacy protocol

**Post Infusion:** Flush IV with 10 mL 0.9% Sodium Chloride Injection, USP at final rate of drug infusion  
**Vital Signs:** At baseline and at every \_\_\_\_\_ minutes during infusion, at completion of post-infusion flush and 30 minutes after completion of post-infusion flush

- Supplies:** Provide infusion pump if needed, IV Pole, back-up peripheral IV kit and all necessary infusion supplies.

ALSO SEE PAGE 2 (LAMZEDE INFUSION REACTION MANAGEMENT ORDERS)

### 6 PROVIDER SIGNATURE ("LAMZEDE Infusion Order")

\_\_\_\_\_  \_\_\_\_\_  
 Product Substitution Permitted Signature Date of Signature Dispense as Written Signature Date of Signature

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by the express authority of the sender to the named addressee.

## INFUSION REACTION MANAGEMENT ORDERS

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_

**7 EMERGENCY MEDICATIONS** - #q.s. Refill: x 1yr OR \_\_\_\_ Refills

Diphenhydramine 50 mg/mL \_\_\_\_\_ mg IV if Infusion Reaction  
 Epinephrine 2-Pak 0.3 mg injector IM once for severe bronchospasm/anaphylaxis and call 911 (for patients weighing greater than or equal to 30kg)  
 Epinephrine 2-Pak 0.15 mg injector - IM once for severe bronchospasm/anaphylaxis and call 911 (for patients weighing < 30kg)  
 Corticosteroid: \_\_\_\_\_  
 0.9% Saline 250 mL - administer at 50 mL/hr once LAMZEDE infusion stops:  
 0.9% Saline \_\_\_\_mL - administer at \_\_\_\_mL/hr once LAMZEDE infusion stops:  
**Supplies:** Provide infusion pump if needed, IV Pole, back-up peripheral IV kit and all necessary infusion supplies.

EXAMPLES OF COMPLEX THERAPY INFUSION REACTIONS			
• Fever	• Rash/Itching	• Abdominal Pain	• Dyspnea
• Chills/Rigors	• Swelling/Edema	• Irritability	• Respiratory Distress
• Headache	• Nausea/Vomiting	• Hypotension	

**INSTRUCTIONS DURING REACTION**

**1) STOP LAMZEDE** and start 0.9% normal saline at 50 mL/hr.  
 Other Rate: \_\_\_\_mL/hr

**2) ADMINISTER EMERGENCY MEDS FROM BOX 7 ACCORDING TO PHYSICIAN ORDERS**  
 For severe anaphylaxis, administer appropriate Epinephrine Autoinjector IM - may repeat in 20 minutes if needed. Call 911.

**3) CALL PHYSICIAN**

**8 PROVIDER SIGNATURE ("LAMZEDE Infusion Reaction Management Orders")**

X Product Substitution Permitted Signature	_____ Date of Signature	X Dispense as Written Signature	_____ Date of Signature
---	----------------------------	------------------------------------	----------------------------

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by the express authority of the sender to the named addressee.